Coherus Oncology, Inc. (CHRS) Net margin 2016–2025
Coherus Oncology, Inc. (CHRS) net profit margin by fiscal year — reported net income divided by reported revenue.
398.4%FY2025 · since FY2016: -67.2% → 398.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 398.4% | +290.4 pp |
| FY2024 | 108.0% | +19639.4 pp |
| FY2023 | -19531.4% | -19393.1 pp |
| FY2022 | -138.2% | -50.3 pp |
| FY2021 | -87.9% | -115.7 pp |
| FY2020 | 27.8% | +2.6 pp |
| FY2019 | 25.2% | — |
| FY2017 | -15306.6% | -15239.4 pp |
| FY2016 | -67.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice